ReviewDiscover nano2026
Research trends and hotspots of nanomaterials in Alzheimer's disease: bibliometric analysis.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Smart Drug-Delivery Approaches for Enhanced Management of Comorbid Conditions in Alzheimer's Disease.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) is a progressive neurodegenerative disorder with limited clinical treatment options. Nanoparticle technology offers promising new strategies for innovative diagnosis and therapy of AD. However, the rapid development of this field has not been accompanied by a systematic bibliometric analysis. This study applies bibliometric methods to comprehensively evaluate the development trends and prospects of nanoparticle applications in AD research. MATERIALS AND
methodsPublications related to nanomaterials in AD were retrieved from the Web of Science Core Collection. Visualization and analysis were conducted using VOSviewer, CiteSpace, and the Bibliometrix package in R to identify research hotspots in the field.
resultsA total of 2837 publications were included, involving 92 countries/regions, 2953 institutions, and 13,294 authors. China, the Chinese Academy of Sciences, and Xiao-Gang Qu were the most productive country, institution, and author, respectively. The Journal of Controlled Release was the most influential. Among them, Saraiva et al. (J Control Release 235:34-47, 2016) ranked first with 1069 citations, and their research highlights the great potential of nanoparticle drug delivery technology to cross the blood-brain barrier. Emerging keyword trends indicate a shift in research focus toward nasal delivery, extracellular vesicles, graphene quantum dots for diagnostics, and nanostructured lipid carriers for therapy.
conclusionNanomaterial-based AD research is expanding rapidly. Current focus involves developing targeted nanoparticle systems to overcome the blood-brain barrier, mitigate Aβ pathology, and enable early diagnosis. Future work should prioritize mechanistic studies and clinical trials to translate potential into practical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.